Hikma Pharmaceuticals PLC, a multinational group, acquired 97.7% of the share capital of Egyptian company EIMC United Pharmaceuticals for EGP 300m.
HC Securities and Investment (HC) acted as the exclusive financial adviser to Hikma.
Hikma focuses on developing, manufacturing, and marketing a broad range of both branded and non-branded generic and in-licensed products. The group is based primarily in the Middle East and North Africa (MENA) region.
Hikma’s operations are conducted through three businesses: branded, injectable, and generic.
The acquisition of EIMC United marks the third acquisition of this kind for Hikma in Egypt.
This acquisition will further support Hikma in achieving its strategy of increasing its market presence in Egypt, as a key market in the MENA region, as well as penetrating the growing oncology therapeutic segment.
In 2015, Hikma achieved revenues of $1.4bn and a profit, attributable to shareholders, of $252m.
EIMC United Pharmaceuticals was established in 2004 as the first Egyptian pharmaceutical company specialising in oncology and intensive care products.
HC is an investment bank with fully operational offices in Egypt and the UAE.
